Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in pharmacology Jg. 15; S. 1392209
Hauptverfasser:	Jiang, Shuwen, Li, Xiangkun, Xue, Weifang, Xia, Sumei, Wang, Jian, Sai, Yang, Dai, Guangxiu, Su, Weiguo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 2024
Schlagworte:	drug–drug interaction hematological malignancies in vitro in vivo extrapolation pharmacokinetics PI3Kδ tissue distribution hematological malignancies pharmacokinetics PI3Kδ drug–drug interaction in vitro in vivo extrapolation tissue distribution
ISSN:	1663-9812, 1663-9812
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!